<DOC>
	<DOCNO>NCT01161836</DOCNO>
	<brief_summary>This Phase 1 , multi-center , open-label study . During Segment 1 , patient administer single IV administration [ 14C ] -iniparib . During Segment 2 , patient administer iniparib without additional chemotherapy . Acceptable chemotherapy regimen limit previous experience iniparib exists .</brief_summary>
	<brief_title>An Open-label Study Investigating Disposition QT/QTc Interval Effects 400 mg 14C-Iniparib ( 3.7 MBq , 100 ÂµCi )</brief_title>
	<detailed_description />
	<mesh_term>Iniparib</mesh_term>
	<criteria>Male female patient advance solid tumor refractory standard treatment standard treatment exist ; patient must least 18 year old . Additional criterion also require evaluate research staff .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>